Clinical Impact of Circulating MicroRNAs As Blood-based Marker in Childhood Acute Lymphoblastic Leukemia

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2016 Feb 10

PMID 26857279

Citations 19

Authors

Menha Swellam

Nashwa El-Khazragy

Affiliations

Soon will be listed here.

Abstract

Aberrant microRNA (miRNA) expression participates in childhood acute lymphoblastic leukemia (ALL). This study aimed to investigate the expression of miRNA-100, miRNA-196a, and miRNA-146a among childhood ALL and study their correlation with other hematological parameters and different phenotypes. Peripheral blood mononuclear cells (PMNCs) were obtained from 85 childhood ALL and 25 healthy children for the detection of miRNA expression using quantitative real-time PCR. Significant higher median levels were reported for ALL compared to control children. The diagnostic efficacy for miRNA-146a was superior as both sensitivity and specificity were absolute. A significant correlation was observed between higher expression of miRNA-100 and lower platelet and lymphocyte counts; high expression of miRNA-146a showed significant correlation with low total leukocyte count (TLC) and lymphocyte counts. Significant relation was reported between studied miRNAs and different phenotyping. miRNA-100, miRNA-196a, and miRNA-146a have significant role in childhood ALL leukemogenesis, and they may be useful as biological diagnostic molecular markers.

Citing Articles

Advancements in the Regulatory Role of microRNAs in Childhood Acute Lymphoblastic Leukemia: Mechanisms and Clinical Implications.

Deng W Technol Cancer Res Treat. 2024; 23:15330338241273143.

PMID: 39099455 PMC: 11301750. DOI: 10.1177/15330338241273143.

Liquid Biopsy in Head and Neck Cancer: Its Present State and Future Role in Africa.

Temilola D, Adeola H, Grobbelaar J, Chetty M Cells. 2023; 12(22).

PMID: 37998398 PMC: 10670726. DOI: 10.3390/cells12222663.

Circulating Biomarkers Associated with the Diagnosis and Prognosis of B-Cell Progenitor Acute Lymphoblastic Leukemia.

Alvarez-Zuniga C, Garza-Veloz I, Martinez-Rendon J, Ureno-Segura M, Delgado-Enciso I, Martinez-Fierro M Cancers (Basel). 2023; 15(16).

PMID: 37627214 PMC: 10453581. DOI: 10.3390/cancers15164186.

MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia.

Mendiola-Soto D, Barcenas-Lopez D, Perez-Amado C, Cruz-Miranda G, Mejia-Arangure J, Ramirez-Bello J Int J Mol Sci. 2023; 24(6).

PMID: 36982511 PMC: 10049736. DOI: 10.3390/ijms24065436.

The Importance of Selected Dysregulated microRNAs in Diagnosis and Prognosis of Childhood B-Cell Precursor Acute Lymphoblastic Leukemia.

Zietara K, Lejman J, Wojciechowska K, Lejman M Cancers (Basel). 2023; 15(2).

PMID: 36672378 PMC: 9856444. DOI: 10.3390/cancers15020428.

References

Gefen N, Binder V, Zaliova M, Linka Y, Morrow M, Novosel A . Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53. Leukemia. 2009; 24(1):89-96. PMC: 2811577. DOI: 10.1038/leu.2009.208. View

Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y . MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 2009; 60(4):1065-75. DOI: 10.1002/art.24436. View

Taganov K, Boldin M, Chang K, Baltimore D . NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006; 103(33):12481-6. PMC: 1567904. DOI: 10.1073/pnas.0605298103. View

Crazzolara R, Bendall L . Emerging treatments in acute lymphoblastic leukemia. Curr Cancer Drug Targets. 2009; 9(1):19-31. DOI: 10.2174/156800909787314057. View

de Oliveira J, Scrideli C, Brassesco M, Morales A, Pezuk J, de Paula Queiroz R . Differential miRNA expression in childhood acute lymphoblastic leukemia and association with clinical and biological features. Leuk Res. 2011; 36(3):293-8. DOI: 10.1016/j.leukres.2011.10.005. View

Pui C, Robison L, Look A . Acute lymphoblastic leukaemia. Lancet. 2008; 371(9617):1030-43. DOI: 10.1016/S0140-6736(08)60457-2. View

Duyu M, Durmaz B, Gunduz C, Vergin C, Karapinar D, Aksoylar S . Prospective evaluation of whole genome microRNA expression profiling in childhood acute lymphoblastic leukemia. Biomed Res Int. 2014; 2014:967585. PMC: 4053274. DOI: 10.1155/2014/967585. View

Li Q, Liu L, Li W . Identification of circulating microRNAs as biomarkers in diagnosis of hematologic cancers: a meta-analysis. Tumour Biol. 2014; 35(10):10467-78. DOI: 10.1007/s13277-014-2364-4. View

Vitale A, Guarini A, Chiaretti S, Foa R . The changing scene of adult acute lymphoblastic leukemia. Curr Opin Oncol. 2006; 18(6):652-9. DOI: 10.1097/01.cco.0000245317.82391.1b. View

10.

Nguyen H, Tian G, Murph M . Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise?. Front Oncol. 2014; 4:71. PMC: 3986558. DOI: 10.3389/fonc.2014.00071. View

11.

Schotte D, Lange-Turenhout E, Stumpel D, Stam R, Buijs-Gladdines J, Meijerink J . Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia. Haematologica. 2010; 95(10):1675-82. PMC: 2948092. DOI: 10.3324/haematol.2010.023481. View

12.

Zweig M, Campbell G . Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993; 39(4):561-77. View

13.

Zheng Y, Zhang H, Zhang X, Feng D, Luo X, Zeng C . MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia. Oncogene. 2011; 31(1):80-92. PMC: 3253429. DOI: 10.1038/onc.2011.208. View

14.

Git A, Dvinge H, Salmon-Divon M, Osborne M, Kutter C, Hadfield J . Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA. 2010; 16(5):991-1006. PMC: 2856892. DOI: 10.1261/rna.1947110. View

15.

Swellam M, Abdelmaksoud M, Sayed Mahmoud M, Ramadan A, Abdel-Moneem W, Hefny M . Aberrant methylation of APC and RARβ2 genes in breast cancer patients. IUBMB Life. 2015; 67(1):61-8. DOI: 10.1002/iub.1346. View

16.

Yu H, Lindsay J, Feng Z, Frankenberg S, Hu Y, Carone D . Evolution of coding and non-coding genes in HOX clusters of a marsupial. BMC Genomics. 2012; 13:251. PMC: 3541083. DOI: 10.1186/1471-2164-13-251. View

17.

Danen-van Oorschot A, Kuipers J, Arentsen-Peters S, Schotte D, de Haas V, Trka J . Differentially expressed miRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2011; 58(5):715-21. DOI: 10.1002/pbc.23279. View

18.

Cui J . MiR-16 family as potential diagnostic biomarkers for cancer: a systematic review and meta-analysis. Int J Clin Exp Med. 2015; 8(2):1703-14. PMC: 4402746. View

19.

Williams A, Perry M, Moschos S, Larner-Svensson H, Lindsay M . Role of miRNA-146a in the regulation of the innate immune response and cancer. Biochem Soc Trans. 2008; 36(Pt 6):1211-5. DOI: 10.1042/BST0361211. View

20.

Fan Y, Fan J, Huang L, Ye M, Huang Z, Wang Y . Increased expression of microRNA-196a predicts poor prognosis in human ovarian carcinoma. Int J Clin Exp Pathol. 2015; 8(4):4132-7. PMC: 4466990. View